Synopsis
In 1980, Furchgott and Zawadzki demonstrated that the ability of a blood vessel to relax to acetylcholine is entirely dependent upon the presence of an intact endothelium b1. This startlingly simple and elegant observation heralded a decade of basic research into endothelium-derived vasoactive factors (EDRF). Initially, interest focused on Furchgott's endothelium-derived relaxing factor, which was later identified as the extremely simple molecule, nitric oxide [21. However, bioassay systems suggested the presence of other dilator and constrictor factors. Many of these additional putative factors remain elusive but one constrictor factor was revealed to the world in an impres- sively complete piece of science published in 1988. Yanagisawa, Masaki and colleagues [31 demonstrated the synthesis of a twenty one amino acid peptide which accounted for the constrictor activity found in the supernatant of endothelial cells. They identi- fied its structure, synthesised the peptide, showed its biological activity in vitro and in vivo, proposed mechanisms of action and cloned and sequenced the gene. They named the factor endothelin. The identification of nitric oxide and endothelin has also rekindled interest in established endothelium-derived mediators, including the prostanoids and other arachidonic acid metabolites, and has led to exploration of the possible roles of oxygen radicals such as superoxide. The vascular endothelium has become a major focus for research into disease states or cardiovascular risk factors associated with abnormal vascular tone or reactivity, alterations in cellular adhesion to the vessel wall, increased smooth muscle cell growth and the chronic process of atherogenesis.
From the Back Cover
The vascular endothelium has become an increasing focus of research over the last 15 years. Nitric oxide and endothelin appear to have important and opposing actions on vascular tone, smooth muscle proliferation and platelet/monocyte activation, and endothelial dysfunction affecting the L-arginine/nitric oxide and endothelin systems both appear to be crucial to atherogenesis and to the pathophysiology of many forms of cardiovascular disease. Additionally, a number of new drugs of major clinical interest are now emerging that act favourably to modulate endothelial function and alter the outcome in these conditions. Here, a synthesis of the current understanding of endothelial dysfunction in hypertension and related disorders - and future therapeutic prospects - has been drawn together by a series of internationally recognised leaders in the field.
"About this title" may belong to another edition of this title.
